From: Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life
 | IMRT % (n = 75) | Control % (n = 87) |
---|---|---|
Male (n) | 72 | 64 |
Female (n) | 28 | 36 |
Mean dose primary tumour | 69 Gy | 70 Gy |
Mean age start RT | 59 yrs | 59 yrs |
Mean interval between RT and Questionnaire | 2.3 yrs | 2.9 yrs |
Tumour Site | Â | Â |
   Hypopharynx | 9 | 9 |
   Larynx | 31 | 31 |
   Nasopharynx | 7 | 6 |
   Oral cavity | 7 | 8 |
   Oropharynx | 37 | 45 |
   Thyroid | 7 | 0 |
   Other | 3 | 1 |
T-stage | Â | Â |
   T1 | 16 | 5 |
   T2 | 37 | 27 |
   T3 | 25 | 33 |
   T4 | 22 | 35 |
N-stage | Â | Â |
   N0 | 50 | 39 |
   N1 | 15 | 13 |
   N2 | 36 | 48 |
Larynx | Â | Â |
   T1-2 (n) | 18 | 15 |
   T3-4 (n) | 5 | 12 |
Oropharynx | Â | Â |
   T1-2 (n) | 10 | 5 |
   T3-4 (n) | 14 | 27 |
Concommittant chemotherapy | 39 | 53 |
Surgery | 24 | 15 |
Gastrostomy | 3 | 6 |
Xerostomia related medication | 17 | 20 |